Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19180933 | 0.83 | EPHX1 (0.48) | EPHX2HSD11B1NPC1RAB9A | |
| SCHEMBL26623606 | 0.79 | P2RX7 (0.50) | P2RX7NPC1RAB9ATDP1ALDH1A1 | |
| SCHEMBL19179565 | 0.78 | L3MBTL1 (0.57) | L3MBTL1CSNK1DHSD11B1NPC1RAB9A | |
| SCHEMBL19181909 | 0.77 | NPC1 (0.46) | EPHX2HSD11B1NPC1RAB9A | |
| SCHEMBL3608727 | 0.76 | RAB9A (0.59) | EPHX2L3MBTL1P2RX7ROCK2NPC1 | |
| SCHEMBL3598635 | 0.75 | EPHX2 (0.50) | EPHX2L3MBTL1P2RX7ROCK2NPC1 | |
| SCHEMBL3609248 | 0.74 | KCNJ11 (0.46) | KCNJ11EPHX2L3MBTL1P2RX7CSNK1D | |
| SCHEMBL27729318 | 0.71 | CSNK1D (0.42) | KCNJ11EPHX2L3MBTL1CSNK1DNPC1 | |
| SCHEMBL2437836 | 0.71 | RAB9A (0.48) | EPHX2L3MBTL1P2RX7ROCK2NPC1 | |
| SCHEMBL19181921 | 0.71 | EPHX2 (0.45) | EPHX2HSD11B1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210969-B1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO (JP) | 2021-04-28 | — | — | EP | disclosed |
| CN-107108485-B | KCNQ 2-5 channel activator | 小野药品工业株式会社 | 2020-06-12 | — | — | CN | disclosed |
| US-10676438-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
| US-10676438-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
| US-20200157050-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| US-20200157050-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| US-10570093-B2 | — | — | 2020-02-25 | — | — | US | disclosed |
| US-10570093-B2 | — | — | 2020-02-25 | — | — | US | disclosed |
| US-10196358-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-02-05 | — | — | US | disclosed |
| US-10196358-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-02-05 | — | — | US | disclosed |
| US-20170334855-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20170334855-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-23 | — | — | US | disclosed |
| US-20170334855-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-23 | — | — | US | disclosed |
| US-9809544-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-07 | — | — | US | disclosed |
| US-9809544-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-07 | — | — | US | disclosed |
| US-9809544-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-07 | — | — | US | disclosed |
| EP-3210969-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO Pharmaceutical Co., Ltd. (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-20170217888-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217888-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217888-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD (JP) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570093-B2 | — | KCNQ5, KCNQ2, KCNQ1 | KCNJ11 18/4885EPHX2 1085/4885L3MBTL1 2104/4885 |
| US-20170334855-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | KCNJ11 33/4885EPHX2 2682/4885L3MBTL1 2804/4885 |
| US-20170217888-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | KCNJ11 33/4885EPHX2 2682/4885L3MBTL1 2804/4885 |
| US-20200157050-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | KCNJ11 33/4885EPHX2 2682/4885L3MBTL1 2804/4885 |
| US-10676438-B2 | KCNQ2-5 channel activator | KCNQ5, KCNQ2, KCNQ1 | KCNJ11 33/4885EPHX2 2682/4885L3MBTL1 2804/4885 |
| US-10196358-B2 | KCNQ2-5 channel activator | KCNQ5, KCNQ2, KCNQ1 | KCNJ11 33/4885EPHX2 2682/4885L3MBTL1 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.